A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
A Randomized, Double-blind, 3-Arm Parallel Design Study to Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Cleminorexton Compared With Placebo in Participants With Central Disorders of Hypersomnolence
Narcolepsy Type 1 (NT1) and Narcolepsy Type 2 (NT2) are rare conditions that make people feel very sleepy during the day (often referred to as excessive daytime sleepiness [EDS]). People living with these conditions might find it hard to stay alert and pay attention when they are at school, working, driving, or performing other daily activities.
While all conditions result in feeling sleepy, there are some differences in other common symptoms:
- NT1: People with NT1 often feel very tired during the day and experience cataplexy. Cataplexy is a sudden loss of muscle strength, which can cause someone to collapse or lose control of their muscles for a short time. This is often triggered by strong emotions, such as laughter or surprise. They may also have trouble sleeping well at night.
- NT2: People with NT2 feel sleepy during the day, just like NT1, but they do not have cataplexy.
Orexin is a protein in the brain that helps coordinate a system that plays an important role in helping people to stay awake during the daytime. Cleminorexton is designed to mimic the action of orexin. The purpose of this study is to see how safe and tolerable cleminorexton is in NT1 and NT2 and learn about what the drug does to the body. Another goal of the study is to see if cleminorexton can help people with NT1 and NT2 feel less sleepy and make other symptoms better.
研究概览
详细说明
The SAPPHIRE Clinical Trial
The Sponsor may in the future, through a protocol amendment, expand the protocol to include participants with idiopathic hypersomnia (IH) in Cohort C.
研究类型
注册 (估计的)
阶段
- 阶段2
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Centessa Pharmaceuticals
- 电话号码:617-468-5770
- 邮箱:ORX750trials@centessa.com
学习地点
-
-
Alabama
-
Birmingham、Alabama、美国、35213
- 招聘中
- Birmingham, Alabama
-
-
Colorado
-
Colorado Springs、Colorado、美国、80918
- 招聘中
- Colorado Springs, Colorado
-
-
Florida
-
Brandon、Florida、美国、33511
- 招聘中
- Brandon, Florida
-
Miami、Florida、美国、33155
- 招聘中
- Miami, Florida
-
Miami、Florida、美国、33176
- 招聘中
- Miami, Florida
-
Miami、Florida、美国、33166
- 招聘中
- Miami, Florida
-
Miami、Florida、美国、33186
- 招聘中
- Miami, Florida
-
Miami Lakes、Florida、美国、33014
- 招聘中
- Miami Lakes, Florida
-
Orlando、Florida、美国、32807
- 招聘中
- Orlando, Florida
-
St. Petersburg、Florida、美国、33707
- 招聘中
- St. Petersburg, Florida
-
-
Georgia
-
Atlanta、Georgia、美国、30328
- 招聘中
- Atlanta, Georgia
-
Rincon、Georgia、美国、31326
- 招聘中
- Rincon, Georgia
-
Stockbridge、Georgia、美国、30281
- 招聘中
- Stockbridge, Georgia
-
-
Michigan
-
Lansing、Michigan、美国、48911
- 招聘中
- Lansing, Michigan
-
-
Mississippi
-
Flowood、Mississippi、美国、39232
- 招聘中
- Flowood Mississippi
-
-
North Carolina
-
Denver、North Carolina、美国、28037
- 招聘中
- Denver, North Carolina
-
Huntersville、North Carolina、美国、28078
- 招聘中
- Huntersville, North Carolina
-
-
Ohio
-
Cincinnati、Ohio、美国、45245
- 招聘中
- Cincinnati, Ohio
-
Dublin、Ohio、美国、43017
- 招聘中
- Dublin, Ohio
-
-
South Carolina
-
Columbia、South Carolina、美国、29201
- 招聘中
- Columbia, South Carolina
-
-
Texas
-
Austin、Texas、美国、78731
- 招聘中
- Austin, Texas
-
Dallas、Texas、美国、75251
- 招聘中
- Dallas, Texas
-
Frisco、Texas、美国、75033
- 招聘中
- Frisco, Texas
-
Houston、Texas、美国、77070
- 招聘中
- Houston, Texas
-
San Antonio、Texas、美国、78229
- 招聘中
- San Antonio, Texas
-
Sugar Land、Texas、美国、77478
- 招聘中
- Sugar Land, Texas
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
- 18-70 years of age
- Body Mass Index (BMI) within the range ≥ 17.0 and ≤ 45 kg/m^2 (inclusive)
- Meets the diagnostic criteria of Narcolepsy Type 1 (NT1) or Type 2 (NT2) according to International Classification of Sleep Disorders, 3rd edition, Text Revision edition (ICSD-3-TR) criteria
- Is willing and able to discontinue all medications used for the treatment of narcolepsy
- Is willing and able to adhere to additional protocol requirements
Key Exclusion Criteria:
- Medical disorder other than NT1 or NT2, that is associated with excessive daytime sleepiness (EDS)
- Presence of significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, hematological, malignancy, endocrine, neurological or psychiatric disease
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Group A - Narcolepsy Type 1 (Dose 1)
|
Oral cleminorexton capsule |
|
实验性的:Group A - Narcolepsy Type 1 (Dose 2)
|
Oral cleminorexton capsule |
|
安慰剂比较:Group A - Narcolepsy Type 1 (placebo)
|
matching placebo capsule |
|
实验性的:Group B - Narcolepsy Type 2 (Dose 1)
|
Oral cleminorexton capsule |
|
实验性的:Group B - Narcolepsy Type 2 (Dose 2)
|
Oral cleminorexton capsule |
|
安慰剂比较:Group B - Narcolepsy Type 2 (placebo)
|
matching placebo capsule |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Change from baseline in mean sleep latency (average of the first 4 trials) on the Maintenance of Wakefulness Test (MWT)
大体时间:Baseline to week 12
|
Baseline to week 12
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from baseline in Epworth Sleepiness Scale (ESS) total score
大体时间:Baseline to Week 12
|
Baseline to Week 12
|
|
|
Incidence, Severity, and casual relationship of participants with Treatment Emergent Adverse Events (TEAEs)
大体时间:Baseline to Week 12
|
Baseline to Week 12
|
|
|
Number of participants with abnormal changes from baseline in clinical laboratory tests
大体时间:Baseline to Week 12
|
Baseline to Week 12
|
|
|
Number of participants with abnormal changes from baseline in vital signs
大体时间:Baseline to Week 12
|
Baseline to Week 12
|
|
|
Number of participants with abnormal changes from baseline in 12-lead electrocardiograms (ECGs)
大体时间:Baseline to Week 12
|
Baseline to Week 12
|
|
|
Number of participants with at least 1 endorsement of Item 4 or 5 on Columbia-Suicide Severity Rating Scale (C-SSRS)
大体时间:Baseline to Week 12
|
Baseline to Week 12
|
|
|
Cmax: Maximum observed plasma concentration
大体时间:Baseline to Week 12
|
Baseline to Week 12
|
|
|
Tmax: Time of Maximum Concentration for cleminorexton
大体时间:Baseline to Week 12
|
Baseline to Week 12
|
|
|
AUC: Area under the plasma concentration-time curve
大体时间:Baseline to Week 12
|
Baseline to Week 12
|
|
|
Weekly Cataplexy Rate (WCR)
大体时间:Week 12
|
Measurement specific to Group A |
Week 12
|
|
Change from baseline in Narcolepsy Severity Scale for Clinical Trials (NSS-CT)
大体时间:Baseline to Week 12
|
Measurement specific to Group A |
Baseline to Week 12
|
|
Change from baseline in Narcolepsy Severity Scale-2 for Clinical Trials (NSS2-CT) total score
大体时间:Baseline to Week 12
|
Measurement specific to Group B |
Baseline to Week 12
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- ORX750-004
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.